Randomized Trial of Fulvestrant With or Without Dasatinib in Men and Postmenopausal Women Who Have Hormone Receptor-positive Advanced Breast Cancer Previously Treated With an Aromatase Inhibitor

Status:	Completed
Conditions:	Breast Cancer, Cancer
Therapuetic Areas:	Oncology
Healthy:	No
Age Range:	18 - Any
Updated:	5/27/2016
Start Date:	September 2008
End Date:	January 2014

Phase II Randomized Trial of Fulvestrant With or Without Dasatinib in Men and Postmenopausal Women Who Have Hormone Receptor-positive Advanced Breast Cancer Previously Treated With an Aromatase Inhibitor

The purpose of this study is to find out what effect the combination of fulvestrant
(Faslodex) and dasatinib (Sprycel) has on advanced breast cancer compared to fulvestrant
alone.

For more information regarding Bristol-Myers Squibb (BMS) clinical trial participation,
please visit www.BMSStudyConnect.com.

Inclusion Criteria:

- Histologically confirmed hormone receptor positive (HR+) [(estrogen receptor (ER+)
and/or progesterone receptors(PgR+)] breast cancer according to immunohistochemistry
(IHC)

- Measureable or evaluable-only disease

- human epidermal growth factor receptor 2+ (HER2+) or HER2- breast cancer

- Males and females ≥18 years of age

- Females are post menopausal or surgically sterile

- Recurrent or progressive advanced breast cancer (locally-advanced or metastatic),
that has progressed: (a) during or within 12 months after completion of adjuvant
Aromatase Inhibitor (AI) treatment OR (b) during AI treatment in advanced setting
(metastatic therapy)

Exclusion Criteria:

- Pregnant or breast feeding

- >1 chemotherapy regimen for advanced disease

- Pleural or pericardial effusion

- Serious cardiac condition

We found this trial at

sites

Northwest Cancer Specialists, Pc

Portland, Oregon 97213

from

Portland, OR